Contrasting Histogenics Corporation (HSGX) and The Competition

Histogenics Corporation (NASDAQ: HSGX) is one of 116 public companies in the “Pharmaceuticals” industry, but how does it compare to its rivals? We will compare Histogenics Corporation to related companies based on the strength of its institutional ownership, analyst recommendations, earnings, dividends, risk, profitability and valuation.

Earnings & Valuation

This table compares Histogenics Corporation and its rivals gross revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Histogenics Corporation N/A -$25.96 million -1.15
Histogenics Corporation Competitors $8.20 billion $2.68 billion -0.88

Histogenics Corporation’s rivals have higher revenue and earnings than Histogenics Corporation. Histogenics Corporation is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of current ratings for Histogenics Corporation and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Histogenics Corporation 0 0 2 0 3.00
Histogenics Corporation Competitors 836 3751 6775 185 2.55

Histogenics Corporation presently has a consensus price target of $4.00, indicating a potential upside of 87.79%. As a group, “Pharmaceuticals” companies have a potential upside of 27.87%. Given Histogenics Corporation’s stronger consensus rating and higher possible upside, equities analysts clearly believe Histogenics Corporation is more favorable than its rivals.

Institutional & Insider Ownership

50.1% of Histogenics Corporation shares are held by institutional investors. Comparatively, 43.7% of shares of all “Pharmaceuticals” companies are held by institutional investors. 23.8% of Histogenics Corporation shares are held by insiders. Comparatively, 11.8% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility & Risk

Histogenics Corporation has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500. Comparatively, Histogenics Corporation’s rivals have a beta of 0.90, suggesting that their average share price is 10% less volatile than the S&P 500.

Profitability

This table compares Histogenics Corporation and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Histogenics Corporation N/A -440.61% -86.43%
Histogenics Corporation Competitors -2,859.75% -67.91% -9.23%

Summary

Histogenics Corporation beats its rivals on 7 of the 12 factors compared.

About Histogenics Corporation

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. NeoCart is a cartilage-like implant created using a patient’s own cartilage cells through a series of tissue engineering processes. The patient’s cells are separated from a tissue biopsy specimen extracted from the patient and multiplied in its laboratory. The cells are then infused into its scaffold that provides structure for the developing implant. Before NeoCart is implanted in a patient, the cell- and scaffold construct undergoes a bioengineering process in the Company’s Tissue Engineering Processor (TEP). The Company has operations in the United States and Israel.

Receive News & Ratings for Histogenics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply